Characterization of secondary GI lesions with anaplastic large-cell (Ki-1) lymphoma: a first report of two cases.
Matsumoto
Hiroshi
H
Division of Gastroenterology, Department of Internal Medicine, Kawaski Medical School, Okayama, Japan.
Koga
Hideki
H
Honda
Keisuke
K
Sadahira
Yoshito
Y
Suetugu
Yoshimasa
Y
Mikami
Makoto
M
Nakanishi
Hidekazu
H
Yata
Ken-ichirou
K
Wada
Hideho
H
Sugihara
Takashi
T
Haruma
Ken
K
D000328:Adult; D000077548:Anaplastic Lymphoma Kinase; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy / Q000201:enzymology* / Q000473:pathology*; D006801:Humans; D017728:Lymphoma, Large-Cell, Anaplastic / Q000188:drug therapy / Q000201:enzymology* / Q000473:pathology*; D011239:Prednisolone / Q000627:therapeutic use; D011505:Protein-Tyrosine Kinases / Q000378:metabolism*; D020794:Receptor Protein-Tyrosine Kinases; D014750:Vincristine / Q000627:therapeutic use
D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; D011505:Protein-Tyrosine Kinases; D020794:Receptor Protein-Tyrosine Kinases